Nuvation Bio INC Form 4 insider transactions

Kim D.lickenstaff, a director of Nuvation Bio Inc., acquired stock options for 200,801 shares of Class A Common Stock on September 3, 2024.

Robert B. Bazemore, a director of Nuvation Bio Inc., reports the acquisition of stock options.

Wang Junyuan Jerry, CEO of AnHeart Therapeutics Ltd. and a director of Nuvation Bio Inc., reports the acquisition and conversion of Series A Preferred Stock and warrants into Class A Common Stock following the satisfaction of a convertibility condition related to the merger with AnHeart.

Director Cui Xiangmin reports the conversion of Series A Preferred Stock to Class A Common Stock and the exercisability of warrants following the satisfaction of the Convertibility Condition related to the AnHeart Therapeutics merger.

Director Cui Xiangmin reports purchasing 277,895 shares of Nuvation Bio Inc. at an average price of $2.97.

Director Cui Xiangmin reports multiple purchases of Nuvation Bio Inc. (NUVB) Class A Common Stock through associated investment funds.

Director Kim D. Blickenstaff purchased 172,189 shares of Nuvation Bio Inc. at an average price of $2.9043 on June 11, 2024.

Director Daniel G. Welch exercised stock options at Nuvation Bio Inc., resulting in an increase in his beneficial ownership of Class A Common Stock.

Director Cui Xiangmin reports acquiring shares of Nuvation Bio Inc. through entities associated with Decheng Capital, following a merger with AnHeart Therapeutics Ltd.

Colleen Sjogren, Chief Commercial Officer of Nuvation Bio Inc., reports the acquisition of stock options for 750,000 shares of Class A Common Stock.

Following the merger between Nuvation Bio Inc. and AnHeart Therapeutics, CEO Junyuan Jerry Wang acquired shares and options in Nuvation Bio, reflecting changes in beneficial ownership.

Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio Inc., reports the acquisition of 500,000 stock options.

Stacy Markel, Chief People Officer of Nuvation Bio Inc., reports the acquisition of stock options and shares under the company's employee stock purchase plan.

Moses Makunje, VP of Finance at Nuvation Bio Inc., reports the acquisition of 250,000 Class A Common Stock options.

David C. Hanley, Chief Technical Operations Officer of Nuvation Bio, reports acquisition of shares and stock options.

Gary Hattersley, Chief Scientific Officer of Nuvation Bio Inc., was granted stock options to purchase 500,000 shares of Class A Common Stock.

Dongfang Liu, Chief Medical Officer of Nuvation Bio Inc., reports acquisition of shares and stock options in the company.

Nuvation Bio's CEO, David Hung, reports the acquisition of 2,000,000 stock options with an exercise price of $1.87, vesting over four years.